Mobile

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24 or 48 Weeks of GS-9190, in Combination with Peginterferon Alfa 2a and Ribavirin, to 48 Weeks of Peginterferon Alfa 2a and Ri...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-004527-31

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24 or 48 Weeks of GS-9190, in Combination with Peginterferon Alfa 2a and Ribavirin, to 48 Weeks of Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic Hepatitis C Virus (HCV) Infection

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare the early antiviral activity (complete early virologic response rate; cEVR) of GS-9190 versus placebo, in combination with peginterferon alfa 2a (PEG) and ribavirin (RIBA), following 12 weeks of therapy

Critère d'inclusion

  • Genotype-1 Chronic Hepatitis C Virus (HCV) Infection

Liens